Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Novavax, Inc. (NASDAQ:NVAX)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Novavax, Inc. (NASDAQ:NVAX) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 15,407 shares of the biopharmaceutical company’s stock, valued at approximately $99,000.

Other large investors have also modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in Novavax during the 4th quarter valued at about $27,000. Kitching Partners LLC acquired a new position in Novavax in the 4th quarter valued at about $89,000. GAMMA Investing LLC grew its position in Novavax by 2,272.5% in the 1st quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 11,340 shares in the last quarter. Syon Capital LLC acquired a new position in Novavax in the 4th quarter valued at about $128,000. Finally, Summit Investment Advisors Inc. grew its position in Novavax by 16.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 16,126 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 2,287 shares in the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on NVAX. JPMorgan Chase & Co. dropped their target price on Novavax from $9.00 to $7.00 and set an “underweight” rating for the company in a research report on Friday, May 9th. B. Riley restated a “buy” rating on shares of Novavax in a report on Monday, May 19th. Bank of America cut their price target on Novavax from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, July 22nd. Finally, Citigroup assumed coverage on Novavax in a report on Tuesday, June 17th. They set a “sell” rating and a $6.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $15.86.

Novavax Stock Performance

NVAX opened at $6.73 on Wednesday. Novavax, Inc. has a one year low of $5.01 and a one year high of $15.22. The company has a market cap of $1.09 billion, a P/E ratio of 2.54, a PEG ratio of 0.08 and a beta of 2.50. The business’s 50-day simple moving average is $6.92 and its 200-day simple moving average is $7.21.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $2.22. Novavax had a negative return on equity of 115.51% and a net margin of 38.14%. The business had revenue of $666.66 million for the quarter, compared to the consensus estimate of $204.08 million. During the same quarter in the prior year, the business posted ($1.05) EPS. The business’s revenue for the quarter was up 610.3% on a year-over-year basis. As a group, analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.